GlassScriptPhysician profile
Majid Rahimifar
NPI 1528018785
$29,551.97
in general payments reported to CMS, 2019-2025
20 companies · $21.39 in 2025
The $21.39 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $128 · 2021: $233 · 2022: $239 · 2023: $29K · 2025: $21.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $29K · Food and Beverage: $51.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $28,750.87 |
| Food and Beverage | $51.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $28,750.87 | 2023 | |
| Livanova USA, INC. | $109.55 | 2019-2021 | |
| Eisai INC. | $94.72 | 2019-2021 | |
| Emd Serono, INC. | $83.03 | 2021-2022 | |
| Acorda Therapeutics, INC | $80.46 | 2020-2022 | |
| Cerapedics INC. | $73.35 | 2022 | |
| Merz Pharmaceuticals, LLC | $57.93 | 2021-2023 | Xeomin |
| Abbott Laboratories | $45.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $38.72 | 2021 | |
| Stryker Corporation | $35.96 | 2019-2020 | |
| Axonics, INC. | $28.65 | 2020-2021 | |
| Titan Spine, LLC | $27.98 | 2019 | |
| Merck Sharp & Dohme LLC | $21.39 | 2025 | Bridion |
| Integra Lifesciences Corporation | $20.52 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.35 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $17.10 | 2022 | |
| Abbvie INC. | $13.10 | 2022 | |
| Allergan, INC. | $12.31 | 2020 | |
| Medtronic, INC. | $11.64 | 2022 | |
| Boston Scientific Corporation | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Majid Rahimifar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.